Yusongyuan Pharmaceutical Co. Ltd.

Primary Objective: To investigate the differences in pharmacokinetic behavior between a single oral dose of the test formulation racecadotril (10 mg, manufactured by Yusongyuan Pharmaceutical Co., Ltd.) and the reference formulation racecadotril (Tiorfan®, 10 mg, manufactured by SOPHARTEX, certified by Bioprojet Europe Ltd.) after a meal, and to preliminarily evaluate the bioequivalence of the test formulation (T) and the reference formulation (R), providing a reference for the rationality of blood collection time points and sample size design in the formal trial. Secondary Objective: To evaluate the safety of a single oral dose of the test formulation racecadotril and the reference formulation racecadotril (Tiorfan®) after a meal in Chinese healthy participants.

Main study objectives: To study the pharmacokinetics of the test preparation Olmesartan medoxomil amlodipine tablets (specifications: Olmesartan medoxomil 20mg/amlodipine besylate 5mg (calculated as amlodipine), produced by Yusongyuan Pharmaceutical Co., Ltd.) and the reference preparation Olmesartan medoxomil amlodipine tablets (specifications: Olmesartan medoxomil 20mg/amlodipine besylate 5mg (calculated as amlodipine), produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objectives: To evaluate the safety of the test preparation and reference preparation of Olmesartan medoxomil amlodipine tablets in healthy adult subjects after a single oral administration in the fasting and fed state.

Main study objectives To study the pharmacokinetics of the test preparation sacubitril-valsartan sodium tablets (specification: 100 mg, produced by Yusongyuan Pharmaceutical Co., Ltd.) and the reference preparation sacubitril-valsartan sodium tablets (Noxinto®, specification: 100 mg, produced by Novartis Singapore Pharmaceutical Manufacturing Private. Ltd., licensed by Novartis Pharma Schweiz AG) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objectives To study the safety of the test preparation sacubitril-valsartan sodium tablets and the reference preparation sacubitril-valsartan sodium tablets in healthy adult subjects after a single oral administration in the fasting and fed state.